Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically documented, locally advanced or metastatic NSCLC
Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens available or at least 12 unstained, freshly cut serial sections with associated pathology report that are evaluable for PD-L1 expression and epidermal growth factor receptor (EGFR) mutation status prior to enrollment, except for known sensitizing EGFR mutations in which case 10 unstained slides are required and there is no need for central testing of EGFR mutation status
Disease progression during or following treatment with a prior platinum-containing regimen for locally advanced, unresectable, inoperable, or metastatic NSCLC, or disease recurrence within 6 months of treatment with a platinum-based adjuvant and/or neoadjuvant regimen or combined modality with curative intent
Measurable disease per RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Life expectancy greater than or equal to (\>/=) 12 weeks
Adequate hematologic and end organ function
Agreement to remain abstinent or use contraceptive methods among women of childbearing potential or male partners of women of childbearing potential
Recovery from all acute toxicities from previous therapy
You may not be if
Active or untreated central nervous system (CNS) metastases
Spinal cord compression not definitively treated or not clinically stable
Leptomeningeal disease
Uncontrolled pleural or pericardial effusions or ascites requiring recurrent drainage
Uncontrolled tumor-related pain
Uncontrolled hypercalcemia
Malignancies other than NSCLC within 5 years prior to randomization, except for those curatively treated with negligible risk of metastasis or death
Pregnant or lactating women
Significant cardiovascular, pulmonary, or autoimmune disease
Severe infection or major surgery within 4 weeks, or antibiotic treatment within 2 weeks prior to randomization
Prior treatment with or hypersensitivity to study drug(s) or related compounds
Inability to discontinue strong cytochrome P450 (CYP) 3A4 inhibitors
Prior allogeneic bone marrow or solid organ transplant
Known PD-L1-negative expression status
Positive human immunodeficiency virus (HIV) or active hepatitis B or C
Receipt of a live attenuated vaccine within 4 weeks prior to randomization
Treatment with systemic immunomodulators within 4 weeks or five half-lives (whichever is shorter) prior to randomization
Treatment with systemic corticosteroids within 2 weeks prior to randomization
Clareo Health | A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy
